News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catalyst Pharmaceutical Partners, Inc. (CPRX) To Present At The JMP Securities 2014 Healthcare Conference



6/19/2014 10:23:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CORAL GABLES, FL, June 1 9 , 201 4 -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) , today announced that the Company will be presenting at the J MP Securities 2014 Healthcare Conference, in New York . Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D. , Catalyst’s Chief Scientific Officer/COO, will provide an overview of the C ompany and its key programs on T ue s day, June 24 th at 1 2: 3 0 p m E T . The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert - Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi - center, pivotal phase 3 trial and has received Breakthrough Therapy Designation from the U. S. Food and Drug Administration (FDA). Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP - 115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergi c signaling, like post - traumatic stress disorder and Tourette Syndrome. CPP - 115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission.

Media/Investor Contacts
David Connolly or Aurora Krause
LaVoie Group
(617) 374 - 8800
dconnolly@lavoiegroup.com
akrause@lavoiegroup.com

Company Contact
Patrick J. McEnany
Catalyst Pharmaceutical Partners, Inc.
Chief Executive Officer
(305) 529 - 2522
pmcenany@catalystpharma.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES